Enveric Biosciences, Inc. (ENVB) Balance Sheet

30Y historyFree accessUpdated daily

The firm maintains an asset-light structure with net PPE declining to $119.9K in 2026Q1, while equity has been severely eroded by an accumulated deficit reaching $116.5 million.

Annual statement

ENVB Balance Sheet

Enveric Biosciences, Inc. (ENVB) balance sheet — 30-year assets, liabilities & shareholders' equity history

Annual Quarterly

Metric	TTM	Dec'25	Dec'24	Dec'23	Dec'22	Dec'21	Dec'20	Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09	Dec'08	Dec'07	Dec'06	Dec'05	Dec'04	Dec'03	Dec'02	Dec'01	Dec'00	Dec'99	Dec'98	Dec'97	Dec'96

Total Current Assets	8.79M	4.94M	2.73M	3.58M	18.43M	17.74M	2.28M	7.6M	10.06M	14.64M	10.06M	7.18M	5.08K	4.47K	5.6K	22.45K	1.13K	1.79K	69.67K	1.61M	328.84K	739.97K	1.27M	970.64K	1.44M	1.45M	2M	1.75M	472.4K	1.92M	2.97M
Cash & Short-Term Investments	8.3M	4.68M	2.24M	2.29M	17.72M	17.36M	1.58M	431.4K	1.37M	4.88M	1.46M	1.96M	5.08K	249	1.38K	18.23K	1.13K	1.79K	66.83K	1.58M	228.94K	550.63K	871.15K	589.8K	858.73K	869.48K	1.47M	1.02M	264.05K	577.41K	1.59M
Cash Only	8.3M	4.68M	2.24M	2.29M	17.72M	17.36M	1.58M	431.4K	1.37M	4.88M	1.38M	1.88M	5.08K	249	1.38K	18.23K	1.13K	1.79K	66.83K	582.02K	228.94K	550.63K	871.15K	589.8K	858.73K	869.48K	1.47M	1.02M	264.05K	577.41K	1.59M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0	82.91K	82.91K	0	0	0	0	0	0	0	1M	0	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	224.61K	0	0	0	6.38M	7.87M	8.84M	8.06M	4.87M	0	0	0	0	0	0	0	0	74.83K	155.23K	325.71K	345.41K	499.02K	442.56K	506.56K	687.6K	134.63K	911.5K	820.86K
Days Sales Outstanding	-	-	-	-	-	-	-	58.38	66.82	66.39	81.39	111.31	-	-	-	-	-	-	-	-	81.97	47.52	107.5	99.33	98.14	100.72	83.97	151.15	29.26	119.62	148.02
Inventory	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-20K	0	12.99K	7.99K	93.25K	296.54K
Days Inventory Outstanding	2.77	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	97.22	21.74	148.15	583.36
Other Current Assets	0	43.25K	233.05K	567.6K	159.78K	0	700.71K	718.53K	818.6K	924.27K	542.24K	343.81K	0	4.22K	4.22K	4.22K	0	0	0	22.99K	25.07K	34.1K	0	0	0	0	26.46K	22.64K	0	146.53K	0
Total Non-Current Assets	150.67K	159.23K	347.96K	718.31K	1.12M	8.98M	1.82M	17.41M	19.58M	37.55M	29.44M	6.66M	0	0	0	0	0	0	0	0	134.74K	156.95K	196.24K	234.51K	305.17K	307.82K	456.02K	372.77K	421.05K	1.24M	1.18M
Property, Plant & Equipment	81.93K	159.23K	305.78K	507.38K	741.3K	470.73K	0	83.13K	58.89K	95.05K	100.24K	73.07K	0	0	0	0	0	0	0	0	3.48K	18.4K	29.53K	42.02K	70.84K	50.59K	108.06K	132.8K	184.14K	586.96K	622.86K
Fixed Asset Turnover	0.00x	-	-	-	-	-	-	480.16x	730.12x	511.25x	360.59x	218.66x	-	-	-	-	-	-	-	-	95.83x	64.80x	37.45x	30.21x	26.20x	31.70x	20.38x	12.50x	9.12x	4.74x	3.25x
Goodwill	0	0	0	0	0	1.59M	0	13.73M	13.73M	21.9M	17.09M	3.47M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	42.18K	210.93K	379.69K	6.92M	1.82M	3.58M	5.78M	9.47M	8.76M	3.11M	0	0	0	0	0	0	0	0	131.26K	138.55K	166.71K	192.49K	225.86K	255.73K	302.79K	687.6K	134.63K	911.5K	820.86K
Long-Term Investments	0	0	0	0	0	0	0	0	0	-6.18M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	68.75K	0	0	0	0	0	0	0	0	6.18M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.47K	1.51K	45.17K	32.18K	0	0	100.83K
Total Assets	8.94M	5.1M	3.08M	4.3M	19.55M	26.72M	4.1M	25.01M	29.64M	52.2M	39.51M	13.83M	5.08K	4.47K	5.6K	22.45K	1.13K	1.79K	69.67K	1.61M	463.58K	896.92K	1.46M	1.21M	1.75M	1.75M	2.46M	2.12M	893.45K	3.17M	4.14M
Asset Turnover	0.00x	-	-	-	-	-	-	1.60x	1.45x	0.93x	0.91x	1.15x	-	-	-	-	-	-	-	0.47x	0.72x	1.33x	0.76x	1.05x	1.06x	0.91x	0.90x	0.78x	1.88x	0.88x	0.49x
Asset Growth %	216.65%	65.32%	-28.31%	-78.01%	-26.82%	552.18%	-83.62%	-15.63%	-43.22%	32.12%	185.57%	-	13.81%	-20.21%	-75.06%	1893.78%	-37.17%	-97.43%	-95.66%	246.22%	-48.31%	-38.74%	21.48%	-30.97%	-0.41%	-28.65%	16.01%	137.06%	-71.77%	-23.57%	-5.88%
Total Current Liabilities	861.48K	918.4K	1.49M	2.34M	4M	2.08M	681.25K	14.38M	14.69M	30.37M	12.71M	8.58M	8.96K	24.7K	25.67K	17.89K	50.64K	11.87K	21.21K	47.9K	87.08K	179.52K	665.13K	177.99K	315.98K	341.54K	806.35K	1.35M	2.45M	1.61M	873.32K
Accounts Payable	682.79K	581.02K	521.75K	1.22M	463.27K	683.39K	681.25K	4.7M	4.38M	5.32M	5.13M	2.6M	0	0	0	0	2.64K	11.87K	5.21K	900	32.14K	14.2K	71.87K	21.47K	39.03K	14.87K	51.78K	234.12K	335.78K	651.38K	403.87K
Days Payables Outstanding	1.32K	1.06K	564.28	1.09K	388.55	365.95	2.06K	53.97	46.98	50.67	63.25	92.71	-	-	-	-	-	-	-	5.19	13.08K	48.85	235.5	64	109.14	56.09	116.49	1.75K	913.34	1.03K	794.51
Short-Term Debt	0	0	0	0	0	0	0	4.88M	5.21M	4.8M	3.49M	1.24M	0	2K	8K	0	0	0	0	9.68K	9.67K	10.44K	66.25K	37.5K	112.5K	112.5K	33.74K	351.89K	872.29K	464.27K	136.3K
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	-2.58M	0	44.84K	0	0	0	0	0	0	0	0	0	0	391.39K	0	0	41.2K	0	344.25K	454.97K	0	0
Other Current Liabilities	178.68K	251.51K	3.09K	350.72K	1.76M	0	0	737.79K	3.8M	20.24M	564.24K	3K	0	0	0	17.89K	40K	0	0	36K	42.1K	106.79K	0	0	0	100K	720.83K	419.6K	783.89K	0	0
Current Ratio	10.21x	5.38x	1.84x	1.53x	4.61x	8.51x	3.35x	0.53x	0.68x	0.48x	0.79x	0.84x	0.57x	0.18x	0.22x	1.25x	0.02x	0.15x	3.29x	33.51x	3.78x	4.12x	1.91x	5.45x	4.56x	4.23x	2.48x	1.29x	0.19x	1.20x	3.40x
Quick Ratio	10.21x	5.38x	1.84x	1.53x	4.61x	8.51x	3.35x	0.53x	0.68x	0.48x	0.79x	0.84x	0.57x	0.18x	0.22x	1.25x	0.02x	0.15x	3.29x	33.51x	3.78x	4.12x	1.91x	5.45x	4.56x	4.29x	2.48x	1.28x	0.19x	1.14x	3.06x
Cash Conversion Cycle	-1.32K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.5K	-862.34	-767.12	-63.13
Total Non-Current Liabilities	0	0	0	0	0	2.33M	0	0	4.19M	2.38M	15.14M	5M	0	2K	8K	0	2.64K	11.87K	5.21K	10.58K	41.81K	24.64K	1.18K	71.77K	1.03K	127.37K	85.52K	0	1.21M	33.36K	540.17K
Long-Term Debt	0	0	0	0	0	0	0	0	0	2.38M	1.54M	5M	0	0	0	0	0	0	0	0	0	0	0	70.75K	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	68.86K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	2.26M	0	0	4.19M	0	13.6M	0	0	0	0	0	0	0	0	0	0	0	1.18K	1.03K	1.03K	0	0	0	0	33.36K	0
Total Liabilities	861.48K	918.4K	1.49M	2.34M	4M	4.41M	681.25K	14.38M	18.88M	32.75M	27.84M	13.58M	8.96K	24.7K	25.67K	17.89K	50.64K	11.87K	21.21K	47.9K	87.08K	179.52K	666.31K	249.77K	317.01K	341.54K	806.35K	1.35M	2.45M	1.64M	873.32K
Total Debt	0	0	0	0	63.82K	176.3K	0	4.88M	5.21M	7.18M	5.03M	6.24M	0	2K	8K	0	0	0	0	9.68K	9.67K	10.44K	66.25K	108.25K	112.5K	112.5K	33.74K	351.89K	872.29K	464.27K	136.3K
Net Debt	-8.3M	-4.68M	-2.24M	-2.29M	-17.66M	-17.18M	-1.58M	4.45M	3.84M	2.3M	3.65M	4.36M	-5.08K	1.75K	6.62K	-18.23K	-1.13K	-1.79K	-66.83K	-572.34K	-219.27K	-540.19K	-804.9K	-481.55K	-746.23K	-756.98K	-1.43M	-670.11K	608.24K	-113.14K	-1.45M
Debt / Equity	0.00x	-	-	-	0.00x	0.01x	-	0.46x	0.48x	0.37x	0.43x	24.12x	-	-	-	-	-	-	-	0.01x	0.03x	0.01x	0.08x	0.11x	0.08x	0.08x	0.02x	0.46x	-	0.30x	0.04x
Debt / EBITDA	-0.00x	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.94x	-	0.08x	0.63x	-	-	-
Net Debt / EBITDA	0.97x	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.23x	-	-3.23x	-1.20x	-	-	-
Interest Coverage	-10329.23x	-82753.59x	-	-4655.56x	-3801.13x	-5469.31x	-14.42x	-6.55x	-13.45x	-18.94x	-7.69x	-2.95x	-	-	-	-	-	-	-10.97x	-	-156.02x	-17.15x	-28.57x	-35.98x	7.08x	-	10.50x	5.09x	-0.50x	-	-
Total Equity	8.08M	4.18M	1.59M	1.96M	15.56M	22.31M	3.42M	10.62M	10.76M	19.44M	11.66M	258.53K	-3.87K	-20.23K	-20.07K	4.55K	-49.52K	-10.07K	48.47K	1.56M	376.5K	717.4K	797.74K	955.38K	1.43M	1.41M	1.65M	768.14K	-1.55M	1.53M	3.27M
Equity Growth %	448.87%	162.28%	-18.58%	-87.42%	-30.26%	553.05%	-67.84%	-1.28%	-44.67%	66.71%	4411.49%	6778.71%	80.86%	-0.8%	-540.53%	109.2%	-391.47%	-120.79%	-96.89%	313.57%	-47.52%	-10.07%	-16.5%	-33.14%	1.22%	-14.49%	114.89%	149.45%	-201.86%	-53.33%	-11.68%
Book Value per Share	2.03	12.48	38.01	10.87	89.83	566.69	356.20	4821.40	27169.44	77779.20	53503.22	1397.48	-35.19	-183.88	-182.42	41.41	-450.15	-91.59	440.63	14155.50	3422.74	6521.84	7252.14	8685.26	12989.38	12832.44	15006.14	6983.06	-14122.64	13864.66	29707.94
Total Shareholders' Equity	8.08M	4.18M	1.59M	1.96M	14.67M	22.31M	3.42M	10.62M	10.76M	19.44M	11.66M	258.53K	-3.87K	-20.23K	-20.07K	4.55K	-49.52K	-10.07K	48.47K	1.56M	376.5K	717.4K	797.74K	955.38K	1.43M	1.41M	1.65M	768.14K	-1.55M	1.53M	3.27M
Common Stock	39.36K	10.62K	6.78K	27.39K	20.78K	6.52K	100.95K	25.22K	423.29K	181.63K	138.86K	118.74K	154.1K	121.42K	121.42K	121.42K	65K	650K	650K	650K	469.77K	469.77K	469.75K	470.16K	474.07K	474.07K	470.88K	461.75K	258.42K	214.1K	191.15K
Retained Earnings	-119.51M	-114.85M	-106.07M	-96.5M	-79.21M	-60.74M	-11.76M	-40.51M	-34.48M	-15M	-3.83M	-1.05M	-47.43M	-47.39M	-47.39M	-47.37M	-47.33M	-47.29M	-45.87M	-45.73M	-46.54M	-46.18M	-46.1M	-45.94M	-45.45M	-45.47M	-45.23M	-45.61M	-45.96M	-40.17M	-35.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-594.68K	-580.04K	-594.52K	-569.75K	-536.73K	-30.8K	-181.28K	60.01K	87K	36.88K	-7.43K	0	0	0	0	0	-65K	0	-1.36M	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	885.03K	0	0	0	0	0	3.38K	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Key Metrics

Growth RegimeContracting

ProfitabilityNegative

Balance SheetVulnerable

Cash FlowBurning

Top Statement Risk

Liquidity and dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Precarious Cash Runway Limits Flexibility

As reported in financial statements, Enveric Biosciences maintains a cash balance of $4.68 million, which, when measured against consistent quarterly burn rates, suggests a limited operational runway that may force the company to seek dilutive capital infusions or strategic partnerships to sustain its research activities.

The current ratio of 11.67 appears artificially high due to the lack of significant current liabilities rather than an abundance of liquid assets. Investors should monitor this metric closely, as the company's inability to generate internal cash flow makes it highly sensitive to capital market conditions.

Asset Base Reflects R&D Focus

Based on the provided balance sheet data, Enveric's asset composition is heavily skewed toward cash and minimal tangible property, with net PPE declining from $507.4K in 2023Q4 to $119.9K in 2026Q1, indicating an asset-light model that prioritizes intellectual property development over physical infrastructure investment.

The absence of significant goodwill or capitalized intangible assets on the balance sheet suggests that the company's core value, its Psybrary platform, is largely expensed through the income statement rather than reflected in book value. This accounting treatment may obscure the true economic value of the company's proprietary chemical library.

Equity Erosion Through Persistent Losses

According to recent SEC filings, the company's equity base has been consistently eroded by accumulated deficits, which reached $116.5 million as of 2026Q1, reflecting the ongoing financial strain of funding pre-clinical biotechnology development without the benefit of offsetting product revenue or commercial milestones.

The persistent negative retained earnings highlight the long-term capital intensity of the business model. Shareholders should remain cautious regarding the potential for further dilution, as the company appears to rely on equity issuance to replenish the equity base and fund its ongoing research operations.

Hidden Risks in Capital Structure

As indicated by the historical data, the company's reliance on equity-based financing to maintain its balance sheet health creates a structural risk where the book value of equity may not accurately represent the long-term viability of the firm's underlying intellectual property assets.

The volatility in total assets and equity over the last ten quarters suggests that the balance sheet is highly reactive to financing events rather than operational progress. This pattern warrants further investigation into whether the company can achieve a sustainable capital structure before its current cash reserves are exhausted.

ENVB — Frequently Asked Questions

Quick answers to the most common questions about buying ENVB stock.

What are the total assets of Enveric Biosciences, Inc. (ENVB)?

As of 2025, Enveric Biosciences, Inc. (ENVB) had total assets of $5.1M including $4.9M in current assets.

How much debt does Enveric Biosciences, Inc. (ENVB) have?

Enveric Biosciences, Inc. (ENVB) carries total debt of $0.0M, offset by $4.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Enveric Biosciences, Inc.?

Enveric Biosciences, Inc. (ENVB) has total shareholders' equity (book value) of $4.2M ($12.48 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Enveric Biosciences, Inc.'s current ratio and liquidity?

Enveric Biosciences, Inc. (ENVB) reported a current ratio of 5.38x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.